Products

Dexcom G6 Pro
Dexcom
Endocrinology & Metabolic AI
Dexcom G6 Pro is a practice-owned continuous glucose monitoring (CGM) system that provides healthcare providers with accurate data for individualized treatment plans for patients with and without diabetes, supporting remote monitoring and integration with Dexcom Clarity.
Dexcom Clarity for Healthcare Professionals
Dexcom
Endocrinology & Metabolic AI
Dexcom Clarity for Healthcare Professionals provides a cloud-based platform for healthcare providers to access, analyze, and interpret continuous glucose monitoring (CGM) data from Dexcom devices, supporting effective diabetes management.

See all 2 products →

About Dexcom

Dexcom, Inc. is a global leader in continuous glucose monitoring (CGM) systems, dedicated to empowering individuals with diabetes to manage their condition effectively. The company develops, manufactures, and distributes a comprehensive line of CGM devices, including the Dexcom G6, G7, and the over-the-counter Stelo, which provide real-time glucose readings without the need for routine fingersticks. These systems offer actionable data to patients and healthcare providers, facilitating optimized diabetes treatment decisions and improving overall quality of life for those with Type 1 and Type 2 diabetes.

In a significant advancement, Dexcom has integrated generative AI capabilities into its offerings, notably with the Stelo continuous glucose monitor. This innovative feature leverages Google Cloud’s Vertex AI platform and Gemini models to provide users with personalized health insights by analyzing data from various sources, including glucose levels, activity, sleep, and meal logs. The AI platform offers tailored recommendations and enhanced weekly insights, acting as a personalized “health coach” to help users understand how lifestyle choices impact their glucose levels and make informed, proactive health decisions.

Beyond direct patient applications, Dexcom’s focus areas extend to broader metabolic health tracking, data analytics, remote patient monitoring, and population health. Through its venture capital arm, Dexcom Ventures, the company also invests in emerging continuous glucose monitoring technologies and devices measuring other analytes, as well as cybersecurity platforms for medical device software. This strategic expansion underscores Dexcom’s commitment to continuous innovation and its vision to transform health management beyond traditional diabetes care.

What Physicians Need to Know

Specialization in Healthcare AI
Dexcom specializes in leveraging AI, particularly generative AI, for continuous glucose monitoring (CGM) data analysis and providing personalized insights for diabetes management and metabolic health. Their AI tools are integrated into their CGM systems to offer actionable information.
Key Differentiators
Dexcom is noted as the first CGM manufacturer to integrate Generative AI into its glucose biosensing technology, offering personalized recommendations based on glucose trends, activity, food, and sleep data. Their systems provide automatic, continuous data streaming to platforms like Dexcom Clarity, ensuring high accuracy and enabling integration with other health apps and insulin delivery systems.
Technology Stack
Their generative AI platform is built on Google Cloud's Vertex AI and Gemini models. Dexcom utilizes proprietary algorithms for data analysis within Dexcom Clarity. The core technology includes advanced biosensors, receivers, and transmitters for CGM, supported by software like the Dexcom Clarity web platform and mobile apps (Dexcom G7/G6 apps). They also offer a Dexcom Real-Time API for third-party integrations.
Value Proposition for Physicians
Dexcom's offerings stand out for physicians by providing comprehensive, interactive reports through Dexcom Clarity, which highlight glucose patterns, trends, and statistics like 'time in range.' This facilitates more informed discussions during patient visits, whether in-person or via telehealth. The automatic data sharing from patient apps to Clarity streamlines data management, and the personalized insights generated by AI can assist in tailoring treatment plans. Additionally, professional CGM options (blinded/unblinded) are available for diagnostic and management purposes.
Physician Tip

To maximize the benefits of Dexcom's healthcare AI tools, physicians should actively leverage Dexcom Clarity for in-depth analysis of patient glucose patterns, time in range, and trends to guide treatment adjustments. Utilize the continuous data streaming feature to monitor patient progress remotely, which can make appointments more efficient and allow for proactive interventions. Engage patients in discussions about the personalized insights generated by Dexcom's AI (e.g., from Stelo or other GenAI-enabled products) to help them understand the direct impact of their lifestyle choices on glucose levels. Consider integrating Dexcom data with other diabetes management tools, such as smart insulin pens or nutrition tracking apps, for a more holistic view of patient health.

Dexcom facilitates robust integrations, offering a Dexcom Real-Time API for authorized third-party developers to securely access CGM data for various health applications and devices. They have established partnerships with AI-powered nutrition tracking apps like RxFood, Undermyfork, Petit Cactus, and Center Health, which can overlay CGM data with meal information. Furthermore, Dexcom CGM systems, such as the G7, can integrate with automated insulin delivery systems like Omnipodu00ae 5, and their Clarity platform supports seamless data sharing with clinics and compatible smart devices.

Products by Dexcom

2 products in the directory

Dexcom G6 Pro
Dexcom
Endocrinology & Metabolic AI
Dexcom G6 Pro is a practice-owned continuous glucose monitoring (CGM) system that provides healthcare providers with accurate data for individualized treatment plans for patients with and without diabetes, supporting remote monitoring and integration with Dexcom Clarity.
Dexcom Clarity for Healthcare Professionals
Dexcom
Endocrinology & Metabolic AI
Dexcom Clarity for Healthcare Professionals provides a cloud-based platform for healthcare providers to access, analyze, and interpret continuous glucose monitoring (CGM) data from Dexcom devices, supporting effective diabetes management.

What the Web Says

Dexcom generally receives mixed to positive reviews for its Continuous Glucose Monitoring (CGM) products, with users often highlighting the life-changing impact of the technology despite some recurring issues. Employer reviews indicate a company with a positive overall culture, good benefits, and opportunities for growth, though some concerns exist regarding management and work-life balance in certain departments.

Overall: Mixed

Strengths

  • Life-changing technology for diabetes management and improved decision-making.
  • Ability to view glucose trends and remote monitoring.
  • Smaller sensor size and shorter warm-up time for newer models (G7).
  • Good compensation and benefits for employees.
  • Positive work environment and culture in many departments.
  • Opportunities for career development and advancement.

Limitations

  • Inaccurate and inconsistent readings, particularly with the G7 and STELO models.
  • Connectivity issues (Bluetooth) with sensors.
  • Adhesive problems and skin irritation.
  • Poor customer service and difficulty with replacements.
  • App functionality issues, including limited features and broken widgets.
  • Management issues, favoritism, and fast-paced/chaotic work environment in some areas.
  • Low pay and lack of growth opportunities in certain roles.

Based on reviews from: Reddit, Comparably, Indeed.com, Medical News Today, Trustpilot, G2, Zippia, YouTube, diaTribe.org, JUICEBOXPODCAST.com

Last updated: 2026-07-21

Videos

News, demos, and interviews about Dexcom.

Loading videos...

Videos load interactively. If none appear, search YouTube for Dexcom →

View all on YouTube

Press & Coverage

pharmaphorum
Dexcom is first to join FDA/CMS health tech pilot
Dexcom has been named the first medical device manufacturer to participate in the FDA's TEMPO (Technology-Enabled Meaningful Patient Outcomes) pilot program, which aims to accelerate the availability of digital health technologies for chronic diseases. The pilot will assess Dexcom's AI-powered Glucose Health Programme, integrating real-time glucose biosensor data with lifestyle factors for people with type 2 diabetes and prediabetes.
2026-07
Dexcom Investor Relations
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Dexcom announced its selection as the first company to participate in the FDA's TEMPO Pilot Program, an initiative to evaluate innovative digital health technologies for chronic disease management and generate real-world evidence. This participation will allow Dexcom to implement an AI-powered glucose health program that integrates data from its G7 and Stelo devices with contextual health information.
2026-07
Dexcom Investor Relations
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults aged 18 and older with diabetes, extending wear and continuity for Canadian users. This authorization further advances Dexcom's vision of glucose biosensing for all.
2026-07
MedGadget
Dexcom Unveils G8 Continuous Glucose Monitor with Advanced Sensing and AI Features
Dexcom unveiled its next-generation continuous glucose monitoring system, Dexcom G8, at its Investor Day, featuring a redesigned silicon chip, updated algorithms, and advanced sensing capabilities. The G8 system is 50% smaller than the current G7 device and is expected to be submitted to the FDA next year with a commercial launch projected for late 2027 or early 2028.
2026-05
FDA
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
Dexcom identified that certain lots of Dexcom G7 sensors, originally designated as scrap, were stolen during the destruction process and subsequently sold by third parties. The company is working with regulators to ensure user safety and investigate the theft.
2026-05
Nasdaq
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Dexcom announced the results of its CONNECT Study, highlighting the significant benefits of continuous glucose monitoring (CGM) for individuals with Type 2 diabetes who do not use insulin. This study reinforces the value of CGM in a broader patient population.
2026-06
Diabetic Medicine
Clinical outcomes of a real- world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes
This real-world prospective study demonstrated that adults with suboptimally controlled diabetes using the Dexcom ONE CGM system experienced significant improvements in HbA1c and participant-reported outcomes. The study included both Type 1 and Type 2 diabetes users, with clinically meaningful increases in Time in Range for Type 2 diabetes participants.
2025-01
Diabetes Care
The Dexcom Community Glucose Monitoring Project: 6-Month Results Using Continuous Glucose Monitoring in Type 2 Diabetes
This community-based initiative provided CGM access to uninsured adults with type 2 diabetes, resulting in a clinically meaningful improvement in A1C and Time in Range after six months. The study highlights the positive impact of CGM in underserved populations with minimal training.
2024-08

Frequently Asked Questions

Dexcom began integrating generative AI into its products and the Stelo biosensor in 2024, utilizing Google Cloud's Vertex AI and Gemini models. This AI analyzes individual health data patterns to provide personalized insights into how lifestyle choices impact glucose levels, aiming to offer more actionable information for patients. The integration also facilitates data sharing with healthcare providers and EHR systems, streamlining clinical workflows and supporting more informed decision-making.
Dexcom is committed to stringent privacy standards, adhering to regulations such as HIPAA and GDPR, and employs the ISO 27001 framework to ensure the confidentiality, integrity, and availability of customer data. They have comprehensive processes, safeguards, and ongoing training to protect patient information. Dexcom's privacy policies detail how data is used, shared, and protected, and they obtain consent for processing personal data, particularly for minors.
Dexcom CGM systems, including G7 and G7 15 Day, are widely covered by commercial insurance and Medicare, with many patients paying $20 or less monthly. The company also offers pharmacy savings programs and patient assistance for those without coverage or with high copays. For healthcare providers, CPT codes are available for CGM setup, training, interpretation, and reporting, which supports reimbursement for clinic services and promotes long-term adoption.
Dexcom offers extensive technical and clinical support through its Global Service and Support specialists for product troubleshooting and assistance. The Dexcom CARE program provides free, expert CGM guidance to help clinics and patients effectively integrate and maximize the benefits of CGM. Additionally, Dexcom provides online resources such as webinars, presentations, prescribing information, and clinic site training to aid healthcare professionals in their practice.
Dexcom has direct CGM data integration with Epic EHR systems, enabling clinicians to view discrete data within their existing workflows, automate data input, and support population health management. They also collaborate with digital health platforms like FriskaAi and Locus Health to integrate CGM data, offering personalized care programs and streamlining chronic disease management. Furthermore, Dexcom CGM systems connect with lifestyle wearables and automated insulin delivery systems, creating a comprehensive digital health ecosystem.
Dexcom demonstrates strong financial stability with increasing revenue and net income, projecting 2025 revenues between $4.6 and $5.1 billion. Their long-term vision includes expanding into the over-the-counter market with products like Stelo, targeting prediabetics and Type 2 non-insulin users, and growing international sales. Dexcom also invests significantly in R&D and strategic collaborations, such as with Google Cloud for AI development, to drive continuous innovation and maintain its competitive edge.

Investors

Who's funded Dexcom.

Related Companies

Visiopharm is a leading provider of AI-driven precision pathology software, catering to both research and diagnostic applications. For physicians, Visiopharm offers advanced tools that transform pathology through image analysis, aiming to enhance precision and productivity in pathology labs. The company has developed nine diagnostic algorithms cleared under IVDR for EU and UK customers, which provide […]

TSI (Transworld Systems Inc.) is a long-standing company primarily known for its debt collection and business process outsourcing services. While they serve various industries, including healthcare, their core offering is focused on accounts receivable management and collections rather than healthcare-specific AI development. They provide solutions to help healthcare providers manage patient accounts, improve cash flow, […]

TrialX is a healthcare AI company specializing in clinical research and space health informatics. The company develops platforms designed to connect patients with clinical trials and facilitate research data collection. Their offerings include an enterprise patient recruitment platform (iConnect) that provides a clinical trials finder (Dory), study website builders, pre-screeners, referral tracking, and volunteer registries. […]

Thinkitive is a global IT services and solutions company that specializes in digital transformation, enterprise application services, outsourced product development, and a testing center of excellence. For physicians, Thinkitive offers a range of AI-driven healthcare solutions designed to streamline clinical and administrative workflows, enhance patient care, and improve operational efficiency. Their services include custom healthcare […]

Taction Software is a U.S.-based healthcare IT and custom software development company specializing in HIPAA-compliant solutions. They build AI-powered applications for healthcare, ranging from rapid clinical AI prototypes to production-grade systems with EHR integration, ambient documentation, and predictive analytics. The company focuses on transforming healthcare delivery through secure, compliant, and innovative software solutions that aim […]

SUPERWISE offers an enterprise AI governance and operations platform designed to help organizations, including those in healthcare, deploy and manage autonomous AI systems with oversight and control. The platform addresses governance, compliance, and operational challenges associated with AI and machine learning deployments. It features real-time guardrails for AI systems, model observability capabilities, and compliance automation, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.